China Investment Roundup: Active Deal-Making And A Record Overseas Acquisition
Executive Summary
Chinese pharma and biotech grew increasingly active in deal-makings in the past months, with the largest outbound acquisition on record in April, a €1.3bn takeover deal made by Creat Group to German Biotest, while domestic big pharmas allotting investment to set up biologic divisions.
You may also be interested in...
China Investment Roundup: Active Deal-Making In Precision Medicine
Winter is coming, yet China’s financial market is still hot for healthcare companies looking at a prosperous period of investment before the year ends. Capital investments from Chinese investors dramatically increased in November, particularly in the precision medicines segment. Although Chinese Creat Group’s expected record-breaking outbound pharmaceutical acquisition deal worth $1.5bn failed to gain US approval, cross-border M&A remained active.
Venture Funding Deals: Cell Medica Raises $73.2m, Tango Dances In With $55m
Novel approaches to infectious diseases and cancer garnered significant VC cash in recent months, including monoclonal antibodies to treat and prevent S. aureus, Cell Medica's next-generation T cell therapies and Tango's platform focused on genetic drivers of cancer.
Fosun On Course To Full Indian Clearance For Gland Buyout
After several rounds of deferral, an Indian investment board has approved Fosun’s acquisition of Gland Pharma, clearing the way for the first Chinese mega acquisition in the Indian pharmaceutical space, although the deal is still expected to require the go ahead from a Cabinet committee on economic affairs.